Century Therapeutics Inc (NASDAQ:IPSC) — Market Cap & Net Worth
Market Cap & Net Worth: Century Therapeutics Inc (IPSC)
Century Therapeutics Inc (NASDAQ:IPSC) has a market capitalization of $336.80 Million ($336.80 Million) as of September 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14386 globally and #3419 in its home market, demonstrating a -4.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Century Therapeutics Inc's stock price $1.86 by its total outstanding shares 181075321 (181.08 Million). Also see Century Therapeutics Inc balance sheet assets for a full breakdown of the balance sheet.
Century Therapeutics Inc Market Cap History: 2021 to 2026
Century Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $2.87 Billion to $336.80 Million (-37.95% CAGR). Also see IPSC cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Century Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.01% | #393 of 976 |
|
NASDAQ Composite
IXIC
|
$42.12 Trillion | 0.00% | #1399 of 3165 |
Weight: Century Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Century Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Century Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IPSC stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.65x
Century Therapeutics Inc's market cap is 1.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.87 Billion | $1.06 Million | -$95.82 Million | 2714.42x | N/A |
| 2022 | $928.92 Million | $5.20 Million | -$130.93 Million | 178.67x | N/A |
| 2023 | $601.17 Million | $2.23 Million | -$136.67 Million | 268.98x | N/A |
| 2024 | $182.89 Million | $6.59 Million | -$126.57 Million | 27.76x | N/A |
| 2025 | $180.13 Million | $109.16 Million | -$9.58 Million | 1.65x | N/A |
Competitor Companies of IPSC by Market Capitalization
Companies near Century Therapeutics Inc in the global market cap rankings as of September 20, 2026. Review Century Therapeutics Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Century Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Century Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Century Therapeutics Inc's market cap moved from $2.87 Billion to $ 336.80 Million, with a yearly change of -37.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $336.80 Million | +86.97% |
| 2025 | $180.13 Million | -1.50% |
| 2024 | $182.89 Million | -69.58% |
| 2023 | $601.17 Million | -35.28% |
| 2022 | $928.92 Million | -67.65% |
| 2021 | $2.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Century Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $336.80 Million USD |
| MoneyControl | $336.80 Million USD |
| MarketWatch | $336.80 Million USD |
| marketcap.company | $336.80 Million USD |
| Reuters | $336.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more